It's a relatively uncommon side effect, affecting around 0.4% of people on semaglutide (around 4,000 out of every million people), so most studies only see a small handful of instances to examine
Endocrine 66 , 157165 (2019)
The smaller vial is above all practical when a research setup is still exploratory or works with limited quantities
(Biochem Pharmacol 2018) documented a reduction of -35% in white adipose tissue, -40% in adipocyte volume, -5.1% in body weight and -30% in plasma cholesterol in just 11 days in obese mice (DIO), without any change in food intake
Heymsfield SB, Coleman LA, Miller R, Rooks DS, Laurent D, Petricoul O, et al
Among the secondary prevention population ( n =95,247 at baseline), widespread SGLT2i use was projected to prevent 5402 non-fatal MIs, 66,490 HF hospitalisations, 2324 ESKD events and 7000 deaths, but increase the number of non-fatal strokes by 996